polatuzumab vedotin

Ukraine

Drugs containing this active substance

  • POLYVI

    The drug is indicated for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL). It is used for both previously untreated cases (in combination with certain therapy regimens) and for the treatment of relapsed or refractory forms of the disease.

    Form: powder for concentrate for infusion solution

    Active substance Dosage
    polatuzumab vedotin 30 mg

    ATC: L01FX14

    Manufacturer: Lonza Ltd (quality control testing (except potency, sterility, and bacterial endotoxins))

  • POLYVI

    The drug is indicated for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL). It is used for both previously untreated cases (in combination with R-CHP) and for the treatment of relapsed or refractory disease (in combination with bendamustine and rituximab).

    Form: powder for concentrate for infusion solution

    Active substance Dosage
    polatuzumab vedotin 140 mg

    ATC: L01FX14

    Manufacturer: Lonza Ltd (quality control testing (except potency, sterility, and bacterial endotoxins))